Position：Hospital President, Chair of HPB Surgery
Department：HPB Surgery
Medical School：Zhejiang University School of Medicine, China
Academic Rank：Professor, Chief Physician
Surgery and comprehensive therapy of hepatic, pancreatic and bililary tumors.
Precision surgery of complicated hepatobiliary and pancreatic diseases, including surgery for hilar cholangiocarcinoma, pancreatic cancer that requires vascular resection and reconstruction, and biliary tract tumor.
Minimally invasive surgery of hepatobiliary and pancreatic tumors, and da Vinci robotic-assisted surgery.
Liver transplantation, including living donor liver transplantation for adults and children, split liver transplantation, etc.
Diagnosis and treatment of other intractable or rare hepatobiliary and pancreatic diseases.
State Scientific and Technological Progress Award, First Prize, 2015
State Scientific and Technological Progress Award, First Prize, 2013
Zhejiang Scientific and Technological Progress Award, First Prize, 2009
State Scientific and Technological Progress Award, Second Prize, 2008
Zhejiang Scientific and Technological Progress Award, First Prize, 2007
Zhejiang Scientific and Technological Progress Award, First Prize, 2005
Zhejiang Scientific and Technological Progress Award, Third Prize, 2001
Zhejiang Scientific and Technological Progress Award, First Prize, 2000
Vice President, Chinese Hospital Association
Standing Committee, Surgery Group, Chinese Medical Association
Standing Committee, Organ Transplantation Group, Chinese Medical Association
Chairman, ERAS Expert Committee, National Health Commission
Chairman, Surgery Group, ERAS Expert Committee, Chinese Medical Doctor Association
Standing Committee, Surgery Group, Chinese Medical Doctor Association
Vice Chairman, Surgery Branch, Robotic surgeon Committee, Chinese Medical Doctor Association
Vice Chairman, Pancreatic Disease Committee, Chinese Research Hospital Association
Vice Chairman, Organ Acquisition and Distribution Management Committee, Chinese Hospital Association
Vice Chairman, Surgery Group, China International Exchange and Promotion Association for Medical and Healthcare
Standing Committee, Pancreatic Disease Expert Committee, Chinese Medical Doctor Association
Vice Chairman, Organ Acquisition and Evaluation Group, Organ Transplantation Association, Chinese Medical Association
Vice Chairman, China Internet Health Industry Alliance
Appointment Chairman, Surgical Oncology Group, Zhejiang Medical Association
Chairman, ERAS Group, Zhejiang Medical Association
Vice Chairman, Surgery Group, Zhejiang Medical Association
Associate Editor-in-Chief, World Journal of Emergency Medicine
Editorial Board Member, Hepatobiliary & Pancreatic Diseases International (HBPD INT)
Editorial Board Member, Chinese Journal of Transplantation
Editorial Board Member, Chinese Journal of Pancreatology
Editorial Board Member, Chinese Journal of Critical Care Medicine
Editorial Board Member, Journal of Translational Medicine
Editorial Board Member, Narrative Medicine
Prof. Wang is the first in China to systematically report on the technology of donor liver recovery and several post-operative key points for living donor liver transplantation.
His team has completed more than 1000 liver transplantations. He has carryed out the first case of Ex Situ Hepatectomy and Liver Autotransplantation as well as the minimally invasive acquisition living donor liver transplantation for children in Zhejiang Province. He is the first to perform living donor liver transplantation on pediatric patients, split liver transplantation and living donor liver transplantation for amino acid metabolism disease at SAHZU, with a 100% survival rate of recipient children, which is leading the world.
Prof. Wang is also devoted to research and development of AI-assisted diagnosis system for liver cancer, whose accuracy of liver segmentation recognition, and the localization and diagnosis of liver cancer rank first in the world.
Prof. Wang has developed a variety of nanomedicines for the treatment of hepatobiliary and pancreatic diseases and the results have been published in authoritative journals such as Adv Sci and Theranostics, etc.
Lisha Yu, Zhaodi Liu, Zongrui Tong, Yihang Ding, Zhefeng Qian, Weilin Wang*, Zhengwei Mao*, Yuan Ding*. Sequential-Crosslinking Fibrin Glue for Rapid and Reinforced Hemostasis, ADVANCED SCIENCE(Weinh), 2023, Dec 10:e2308171.
Yang Du, Yining Chen, Fangyuan Li*, Zhengwei Mao*, Yuan Ding*, Weilin Wang*. Genetically Engineered Cellular Nanovesicle as Targeted DNase I Delivery System for the Clearance of Neutrophil Extracellular Traps in Acute Lung Injury. ADVANCED SCIENCE (Weinh), 2023;10(32):e2303053.
Fangfang Cao, Lulu Jin, Yong Gao, Yuan Ding, Hongyang Wen, Zhefeng Qian, Chenyin Zhang, Liangjie Hong, Huang Yang, Jiaojiao Zhang, Zongrui Tong, Weilin Wang*, Xiaoyuan Chen*, Zhengwei Mao*. Artificial Enzymes-Armed Bifidobacterium Longum Probiotics for Alleviating Intestinal Inflammation and Microbiota Dysbiosis. NATURE NANOTECHNOLOGY, 2023; 18(6): 617-627.
Jiaojiao Zhang, Bingqiang Gao, Binglin Ye, Zhongquan Sun, Zhefeng Qian, Lisha Yu, Yanli Bi, Lie Ma, Yuan Ding*, Yang Du*, Weilin Wang*, Zhengwei Mao*. Mitochondrial-Targeted Delivery of Polyphenol-Mediated Antioxidases Complexes against Pyroptosis and Inflammatory Diseases. ADVANCED MATERIALS, 2023; 35(11):e2208571.
Yang Du, Xiaohui Qian, Fenghao Lin, Bingqiang Gao, Weili Wang, Huang Yang*, Weilin Wang*, Yuan Ding*. A biomimetic nanoplatform for precise reprogramming of tumor-associated macrophages and NIR-II mediated antitumor immune activation. ACTA BIOMATERIALIA. 2023; 162:85-97.
Fangfang Cao, Lulu Jin, Chenyin Zhang, Yong Gao, Zhefeng Qian, Hongyang Wen, Sisi Yang, Ziqiang Ye, Liangjie Hong, Huang Yang, Zongrui Tong, Liang Cheng, Yuan Ding, Weilin Wang, Guocan Yu*, Zhengwei Mao*, Xiaoyuan Chen*. Engineering Clinically Relevant Probiotics with Switchable "Nano-Promoter" and "Nano-Effector" for Precision Tumor Therapy. ADVANCED MATERIALS, 2023 Oct 3：e2304257.
Chaojie Zhu, Qing Wu, Tao Sheng, Jiaqi Shi, Xinyuan Shen, Jicheng Yu, Yang Du, Jie Sun, Tingxizi Liang, Kaixin He, Yuan Ding*, Hongjun Li*, Zhen Gu*, Weilin Wang*. Rationally designed approaches to augment CAR-T therapy for solid tumor treatment. BIOACTIVE MATERIALS, 2023;33: 377-395.
Qing Lin, Shangyou Zheng, Xianjun Yu, Meifu Chen, Yu Zhou, Quanbo Zhou, Chonghui Hu, Jing Gu, Zhongdong Xu, Lin Wang, Yimin Liu, Qingyu Liu, Min Wang, Guolin Li, He Cheng, Dongkai Zhou, Guodong Liu, Zhiqiang Fu, Yu Long, Yixiong Li*, Weilin Wang*, Renyi Qin*, Zhihua Li*, Rufu Chen*. Standard pancreatoduodenectomy versus extended pancreatoduodenectomy with modified retroperitoneal nerve resection in patients with pancreatic head cancer: a multicenter randomized controlled trial. CANCER COMMUNICATIONS (Lond), 2023;43(2): 257-275.
Yuan Ding, Zongrui Tong, Lulu Jin, Binglin Ye, Jiong Zhou*, Zhongquan Sun, Huang Yang, Liangjie Hong, Feihe Huang, Weilin Wang*, Zhengwei Mao*. An NIR Discrete Metallacycle Constructed from Perylene Bisimide and Tetraphenylethylene Fluorophores for Imaging-Guided Cancer Radio-Chemotherapy. ADVANCED MATERIALS, 2022;34(7):e2106388.
Zongrui Tong, Quanshi Guo, Guangyu Xu, Yong Gao, Huang Yang, Yuan Ding*, Weilin Wang*, Zhengwei Mao*. Supramolecular hydrogel-loaded Prussian blue nanoparticles with photothermal and ROS scavenging ability for tumor postoperative treatments. COMPOSITES PART B: ENGINEERING, 2022, May(15): 237.
Huang Yang, Yuan Ding, Zongrui Tong, Xiaohui Qian, Hao Xu, Fenghao Lin, Guoping Sheng*, Liangjie Hong, Weilin Wang*, Zhengwei Mao*. pH-responsive hybrid platelet membrane-coated nanobomb with deep tumor penetration ability and enhanced cancer thermal/chemodynamic therapy. THERANOSTICS，2022;12(9):4250-4268.
Yuan Ding, Sitong Zhang, Zhongquan Sun, Zongrui Tong, Yao Ge, Liuzhi Zhou, Qianhui Xu, Huiping Zhou*, Weilin Wang*. Preclinical validation of silibinin/albumin nanoparticles as an applicable system against acute liver injury, ACTA BIOMATERIALIA, 2022;146:385-395.
Yuan Ding, Zhongquan Sun, Yong Gao, Sitong Zhang, Caixia Yang, Zhefeng Qian, Lulu Jin, Jiaojiao Zhang, Cheng Zeng, Zhengwei Mao*, Weilin Wang*. Plasmon-Driven Catalytic Chemotherapy Augments Cancer Immunotherapy through Induction of Immunogenic Cell Death and Blockage of IDO Pathway. ADVANCED MATERIALS, 2021; 33(34): e2102188.
Yuan Ding, Hao Xu, Chang Xu, Zongrui Tong, Sitong Zhang, Yang Bai, Yining Chen, Qianhui Xu, Liuzhi Zhou, Hao Ding, Zhongquan Sun, Sheng Yan*, Zhengwei Mao*, Weilin Wang*. A Nanomedicine Fabricated from Gold Nanoparticles-Decorated Metal-Organic Framework for Cascade Chemo/Chemodynamic Cancer Therapy, ADVANCED SCIENCE (Weih), 2020; 7(17): 2001060.
Yuan Ding, Zhongquan Sun, Zongrui Tong, Sitong Zhang, Jie Min, Qianhui Xu, Liuzhi Zhou, Zhengwei Mao*, Haibing Xia*, Weilin Wang*. Tumor microenvironment-responsive multifunctional peptide coated ultrasmall gold nanoparticles and their application in cancer radiotherapy, THERANOSTICS, 2020;10:5195-5208.
Yang Yang, Yuan Ding, Bo Fan, Yi Wang, Zhengwei Mao*, Weilin Wang*, Jindan Wu*. Inflammation-targeting polymeric nanoparticles deliver sparfloxacin and tacrolimus for combating acute lung sepsis. JOURNAL OF CONTROLLED RELEASE, 2020;321: 463-474.
The role and pathogenesis of receptor tyrosine kinase RON in invasive metastasis of pancreatic cancer cells. Funding Source: National Natural Science Foundation of China.
Innovative research on precision hepatectomy technology assisted by artificial intelligence vision system. Funding Source: Key R&D Project of Zhejiang Province.
Research on precision diagnosis and treatment of pancreatic cancer. Funding Source: Province-Ministry Cooperative Major Medicine and Health Project of Zhejiang Province.
Novel mechanisms of acquired resistance by hypoxic pancreatic cancer cells towards specific tyrosine kinase inhibitors. Funding Source: National Natural Science Foundation of China.
Establishment and application of early warning technology for pancreatic cancer based on trace DNA detection. Funding Source: Science and Technology Major Project of Zhejiang.
Key technology research and equipment development and verification of medical IoT for digital hospitals. Funding Source: National Science and Technology Major Project.
Research on the correlation between organ transplantation infection and intestinal microecology. Funding Source: 973 Program.
Translational medicine research on early diagnosis and comprehensive therapy of pancreatic cancer. Funding Source: Special Research Project for Public Health Industry.
The mechanism of HSG induce cell apoptosis and inhibit proliferation of hepatocellular carcinoma. Funding Source: National Natural Science Foundation of China.
The mechanism of HSG induce cell apoptosis of pancreatic cancer. Funding Source: Scientific Research Fund of National Health Commission.
Research on early warning and individualized comprehensive therapy technology system for liver cancer. Funding Source: Science and Technology Major Project of Zhejiang Province.
Research on comprehensive therapy technology system of pancreatic cancer. Funding Source: Major Project of the 11th Five-Year Plan.
Prevention of liver graft chronic rejection using the technique of HSG gene transduction. Funding Source: National Natural Science Foundation of China.
Experimental research of HSG gene transfection to prevent chronic rejection of liver transplantation. Funding Source: Province-Ministry Cooperative Project.
88 Jiefang Road,Shangcheng District Hangzhou,China, 310009
1511 Jianghong Road,Binjiang District Hangzhou,China, 310014
300 Yuanju Road, Shangcheng DIstrict, Hangzhou
456 Qidi Road, Xiaoshan District, Hangzhou, China
1 Xihu Avenue, Shangcheng District, Hangzhou
Zijingang Campus of Zhejiang University, 866 Yuhangtang Road, Xihu District, Hangzhou
Please call +86-571-8971 3988 (8am-5pm, Monday through Friday)
Make an appointment online
The Second Affiliated Hospital
Zhejiang University School of Medicine
88 Jiefang Road, Hangzhou, China
+86-571-8731 5108
iao_sahzu@zju.edu.cn
The Needs of Patients and Customers Come First.
The Second Affiliated Hospital Zhejiang University School of Medicine
All Rights Reserved.
